CIBC Asset Management Inc Reduces Stock Holdings in IQVIA Holdings Inc. $IQV

CIBC Asset Management Inc cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 237,368 shares of the medical research company’s stock after selling 45,875 shares during the period. CIBC Asset Management Inc owned about 0.14% of IQVIA worth $45,086,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IQV. Verdence Capital Advisors LLC purchased a new position in shares of IQVIA during the 2nd quarter valued at approximately $3,612,000. Amundi increased its holdings in IQVIA by 46.3% in the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after buying an additional 405,250 shares in the last quarter. Diversified Trust Co raised its position in shares of IQVIA by 57.2% in the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after acquiring an additional 15,487 shares during the period. Act Two Investors LLC purchased a new stake in shares of IQVIA during the 2nd quarter worth about $26,528,000. Finally, Oregon Public Employees Retirement Fund grew its position in shares of IQVIA by 37.1% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 19,463 shares of the medical research company’s stock valued at $3,697,000 after acquiring an additional 5,271 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

IQVIA stock opened at $235.20 on Friday. The company has a fifty day simple moving average of $229.10 and a 200-day simple moving average of $205.90. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $40.05 billion, a price-to-earnings ratio of 32.26, a PEG ratio of 2.39 and a beta of 1.36. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter in the prior year, the company earned $2.84 EPS. IQVIA’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on IQV shares. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday. Stifel Nicolaus increased their target price on IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. BMO Capital Markets initiated coverage on shares of IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 target price on the stock. Finally, UBS Group upped their price target on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $251.06.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.